Data from the SYNCHRONIZE-1 Phase III trial presented at the EASD meeting and in The New England Journal of Medicine show survodutide significantly improves cardiometabolic health markers, reducing HbA1c and improving waist circumference and insulin sensitivity for patients with obesity and type 2 diabetes.
About the Author
